Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chestnut
2023-505674-15-00Phase 3Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of efzimfotase alfa in hypophosphatasia (HPP) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Incidence of TEAEs, TESAEs, AESIs and AEs leading to study intervention discontinuation or interruption. Started Apr 2024; status: terminated.
02
Drugs
efzimfotase alfa
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on 2023-505674-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505674-15-00.